Glytone essentials rejuvenate daily
- Manufacturer
- Glytone | Genesis Pharmaceutical
- Effective date
- 2012-04-25
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 3
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:47:16
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
INACTIVE INGREDIENT SECTION
Inactive Ingredients
Water (Aqua), Glycolic Acid, Cyclomethicone, Ammonium Hydroxide, Butyl Salicylate, Glyceryl Stearate, Butlylene Glycol, Ethylhexyl Palmitate, Pentaerythrityl Tetraisostearate, Cetearyl Alcohol, PEG-150 Stearate, Hydrogenated Avocado Oil, Cetyl Alcohol, Dimethiconol, Glycine Soja (soybean) sterols, Butyrospermum parkii (Shea butter), Petrolatum, Silica, Phenoxyethanol, Dicetyl Phosphate, Glycerin, Tocopheryl Acetate, Disodium EDTA, Xanthan Gum, Hydrolyzed Collagen, Hyaluronic Acid
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients Purpose
Avobenzone 2.00% Sunscreen
Octinoxate 6.00% Sunscreen
OTC - PURPOSE SECTION
INFORMATION FOR PATIENTS SECTION
Other Information
This product is not intended as a sunscreen for sunbathing use. Keep this product away from heat (above 30C/ 86F) and direct sunlight.
WARNINGS SECTION
Warnings
Do not use on damaged or broken skin. When using this product keep out of eyes. Rinse with water to removeStop use and ask a doctor if rash occurs.
If pregnant or breast feeding, ask a health professional before use
For external use only
Do not swallow. If swallowed, get medical help or contact Poison control right away.
Children under 6 months; ask doctor.
INDICATIONS & USAGE SECTION
Uses:
Helps prevent sunburn. If used as directed with other sun protection measures (see directions) decreases the risk of skin cancer and early skin aging caused by sun.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
For external use only. Keep out of reach of children.
DOSAGE & ADMINISTRATION SECTION
Directions
Apply in the morning to cleansed face and neck or as directed by physician.
Apply liberally 15 minutes before sun exposure
Use a water resistant sunscreen if swimming or sweating
Reapply at least every 2 hours.
Sun Protection Measures: Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF value of 15 or higher and other sun protection measures including: limite time in the sun, specially from 10 am to 2pm. Wear long-sleeved shirts, pants, hats and sunglasses.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


Glytone Essentials
rejuvenate
daily cream
broad spectrum
sunscreen SPF 15
Glycolic complex
50 ml e/net wt. 1.7 oz. (50 g)
Lightweight, oil-free cream combines glycolic acid, vitamin E and other clinically proven ingredients with SPF15 broad spectrum protection.
A unique, patented microvesicle delivery system slowly releases skin-enhancing glycolic acid and moisturizing agents throughout the day. Smoothes, softens, and retexturizes skin for a healthy looking complexion.
Shea Butter, Avocado Oil and glycerin-Emollients that sooth the skin.
Hydrolyzed Collagen and Hyaluronic acid-Anti-aging ingredients that moisturize skin and give it volume and fullness.
Exclusive to physicians
Pierre Fabre
Distributed by: Genesis Pharmactical, Inc
Parsippany, NY 07054
Made in USA
1-800-459-8663
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 64760-204-01 | 2023-05-08 | C162847 | 48780-1 | 97449f38-d44e-f6ea-e053-dbdaa90aa703 | Glytone Essentials rejuvenate daily |
| 64760-204-01 | 2019-11-13 | C162847 | 48780-1 | 97449f38-d44e-f6ea-e053-dbdaa90aa703 | Glytone Essentials rejuvenate daily |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Avobenzone | ACTIVE INGREDIENT | G63QQF2NOX | 3 | |
| Octinoxate | ACTIVE INGREDIENT | 4Y5P7MUD51 | 3 | |
| Avobenzone | ACTIVE MOIETY | G63QQF2NOX | 3 | |
| Octinoxate | ACTIVE MOIETY | 4Y5P7MUD51 | 3 | |
| ALPHA-TOCOPHEROL ACETATE | INACTIVE INGREDIENT | 9E8X80D2L0 | 3 | |
| AMMONIA | INACTIVE INGREDIENT | 5138Q19F1X | 3 | |
| AVOCADO OIL | INACTIVE INGREDIENT | 6VNO72PFC1 | 3 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 3 | |
| BUTYLOCTYL SALICYLATE | INACTIVE INGREDIENT | 2EH13UN8D3 | 3 | |
| CETEARYL GLUCOSIDE | INACTIVE INGREDIENT | 09FUA47KNA | 3 | |
| CETOSTEARYL ALCOHOL | INACTIVE INGREDIENT | 2DMT128M1S | 3 | |
| CETYL ALCOHOL | INACTIVE INGREDIENT | 936JST6JCN | 3 | |
| CYCLOMETHICONE | INACTIVE INGREDIENT | NMQ347994Z | 3 | |
| DIHEXADECYL PHOSPHATE | INACTIVE INGREDIENT | 2V6E5WN99N | 3 | |
| EDETATE DISODIUM | INACTIVE INGREDIENT | 7FLD91C86K | 3 | |
| ETHYLHEXYL PALMITATE | INACTIVE INGREDIENT | 2865993309 | 3 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 3 | |
| GLYCERYL MONOSTEARATE | INACTIVE INGREDIENT | 230OU9XXE4 | 3 | |
| GLYCOLIC ACID | INACTIVE INGREDIENT | 0WT12SX38S | 3 | |
| HYALURONIC ACID | INACTIVE INGREDIENT | S270N0TRQY | 3 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 3 | |
| PETROLATUM | INACTIVE INGREDIENT | 4T6H12BN9U | 3 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 3 | |
| PHOSPHATE ION | INACTIVE INGREDIENT | NK08V8K8HR | 3 | |
| POLYETHYLENE GLYCOL 6000 | INACTIVE INGREDIENT | 30IQX730WE | 3 | |
| SHEA BUTTER | INACTIVE INGREDIENT | K49155WL9Y | 3 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 3 | |
| SOYBEAN | INACTIVE INGREDIENT | L7HT8F1ZOD | 3 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 3 | |
| XANTHAN GUM | INACTIVE INGREDIENT | TTV12P4NEE | 3 |
Products#
Every source-derived product name is available through these pages.
- Glytone essentials rejuvenate daily
- Avobenzone, octinoxate
- Avobenzone
- Octinoxate
- WATER
- GLYCOLIC ACID
- CYCLOMETHICONE
- AMMONIA
- BUTYLOCTYL SALICYLATE
- GLYCERYL MONOSTEARATE
- BUTYLENE GLYCOL
- ETHYLHEXYL PALMITATE
- CETOSTEARYL ALCOHOL
- POLYETHYLENE GLYCOL 6000
- AVOCADO OIL
- CETYL ALCOHOL
- SOYBEAN
- SHEA BUTTER
- PETROLATUM
- SILICON DIOXIDE
- PHENOXYETHANOL
- DIHEXADECYL PHOSPHATE
- METHYLPARABEN
- CETEARYL GLUCOSIDE
- PHOSPHATE ION
- GLYCERIN
- ALPHA-TOCOPHEROL ACETATE
- EDETATE DISODIUM
- XANTHAN GUM
- HYALURONIC ACID
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 64760-204 | 64760-204-01 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SYSTEM / TOPICAL | 42 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | AEROSOL, FOAM / TOPICAL | 0.05 %w/w | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SUSPENSION / INTRA-ARTICULAR | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RESPIRATORY (INHALATION) | 0.03 %w/w | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 23 mg | ||
| POLYETHYLENE GLYCOL 6000 | POLYETHYLENE GLYCOL 6000 | 30IQX730WE | CREAM / TOPICAL | 5 %w/w | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / ORAL | 30 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SUSPENSION/ DROPS / ORAL | 22 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| POLYETHYLENE GLYCOL 6000 | POLYETHYLENE GLYCOL 6000 | 30IQX730WE | CAPSULE, EXTENDED RELEASE / ORAL | 302 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION/ DROPS / OPHTHALMIC | 1 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRACARDIAC | 2 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, EMULSION / INTRAVENOUS | 59 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TROCHE / ORAL | 948 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAVENOUS | 0.13 %w/v | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | OINTMENT / TOPICAL | 5 %w/w | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | LIQUID / INTRAVENOUS | 0.03 %w/v | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | EMULSION / TOPICAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / TOPICAL | 0.24 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INFILTRATION | 80 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUPPOSITORY / VAGINAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SOLUTION / ORAL | 84 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL / TOPICAL | 1.16 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM / VAGINAL | 22 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | CREAM / TOPICAL | 14 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / OPHTHALMIC | 58 mg | ||
| POLYETHYLENE GLYCOL 6000 | POLYETHYLENE GLYCOL 6000 | 30IQX730WE | INSERT / VAGINAL | 0.06 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION/ DROPS / OPHTHALMIC | 0.13 %w/v | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET / SUBLINGUAL | 1.23 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IRRIGATION | 2 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | SPONGE / TOPICAL | NA | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | CREAM / VAGINAL | 3 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | POWDER, FOR SUSPENSION / ORAL | 600 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET, FILM COATED / ORAL | 0.08 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SUSPENSION / ORAL | 2553 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 2350 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | TABLET, EFFERVESCENT / ORAL | 32 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / VAGINAL | NA | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | GRANULE, FOR SUSPENSION / ORAL | 4 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | OINTMENT / TOPICAL | 1 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | CREAM / TOPICAL | 57 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC | 0.6 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | EMULSION / TOPICAL | 0.2 %w/w | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | SUSPENSION / OPHTHALMIC | 0.5 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 3.6 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL, FOAM / RECTAL | 17 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / ORAL | 432 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, CHEWABLE / ORAL | 12 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE / DENTAL | 20 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRA-ARTICULAR | 0.24 %w/v | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | EMULSION / ORAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / OPHTHALMIC | 0.06 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / TOPICAL | 216 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| f99eb732-cba2-c5a6-e053-6294a90aa7ed | 854d81f4-12ee-428e-b632-4c87f833b599 | 2023-04-18 | Warnings | 854d81f4-12ee-428e-b632-4c87f833b599 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.